Account
Articles
25.04.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
News
06.04.2022
PMA Insights: Week 14

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
02.03.2022
Use of COVID-19 treatments granted early access 20

According to the National Agency for Drug Safety, there are currently four treatments available thro...

Read more
Insider Insights
01.02.2022
Proposals for reforming public and private health

The report looks at four possible scenarios including most notably the creation of a “grande Sécu...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Early access granted to Xevudy

Notably, the early access scheme was reformed with effect from 1st July 2021.

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more
Articles
16.06.2021
Early market access in France is changing

France's new Social Security Financing Bill (SSFB) will be coming into place no later than July 1st.

Read more
News
09.02.2021
PMA Insights: Week 6

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.